Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways important to cancer cells. It has three clinical-stage product candidates and many preclinical programs that target kinases, cellular metabolism or cell division. The Company’s lead product candidate, rigosertib, is being tested as a single agent and in combination with azacitidine, in clinical trials of patients with myelodysplastic syndromes (MDS) and related cancers. The Company is continuing the Phase II portion of a clinical trial of rigosertib oral in combination with azacitidine for patients with MDS and acute myelogenous leukemia (AML).
